je.st
news
Tag: drug
Cyclenium Pharma Announces Drug Discovery Collaboration Agreement With Astellas Pharma
2015-06-03 06:51:27| drugdiscoveryonline Home Page
Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery and development of novel drug candidates based on proprietary macrocyclic chemistry, announced recently the signing of a drug discovery collaboration agreement with Astellas Pharma Inc., one of the world’s leading pharmaceutical discovery and development companies
Tags: agreement
drug
collaboration
discovery
Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-06-03 06:41:56| drugdiscoveryonline Home Page
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to revusiran, an investigational RNAi therapeutic, for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)
Tags: united
states
united states
food
Beryllium Develops An MCL-1 Platform For Structure-Guided Drug Discovery In Collaboration With The Broad Institute
2015-06-03 06:25:44| drugdiscoveryonline Home Page
Beryllium, a scientific research services company engaging in collaborations with commercial and academic partners, recently announced the development of an MCL-1 platform for structure-guided drug discovery
Tags: the
institute
drug
broad
Bruker Announces MALDI PharmaPulse, A Breakthrough High-Throughput Screening (HTS) Solution For Drug Discovery
2015-06-03 06:14:31| drugdiscoveryonline Home Page
At the 63rd ASMS Conference on Mass Spectrometry and Allied Topics, Bruker recently announced a new high-throughput screening (HTS) solution designed to help pharmaceutical companies achieve high throughput, lower cost and higher specificity in drug discovery
Tags: solution
drug
discovery
screening
Weill Cornell Medical College And Cellectis Announce Research Alliance Advancing Drug Discovery And The Translation Of Novel Immunotherapies In Leukemia
2015-06-03 05:49:21| drugdiscoveryonline Home Page
Regulatory News: Weill Cornell Medical College and Cellectis have entered into a strategic translational research alliance to accelerate the development of a targeted immunotherapy for patients with acute myelogenous leukemia (AML), a deadly blood cancer
Tags: in
research
college
medical
Sites : [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] next »